跳至主要内容
临床试验/NCT05621590
NCT05621590已完成早期 1 期

MLC901 in Hypoxic-ischemic Brain Injury Patients; A Double-blind, Randomized Placebo-controlled Trial

Shahid Beheshti University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2020年3月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
已完成
入组人数
35
试验地点
1
主要终点
neurofunctional outcome using Glasgow Outcome Scale (GOS)

研究概览

简要总结

In a randomized, placebo-controlled trial, 35 patients with HIBI were randomly designated to receive either MLC901 or placebo capsules over six months.

We evaluated patients in two groups by modified Rankin Scale (mRS) and Glasgow outcome scale (GOS) to examine their state of disability and recovery

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
14 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • an initial cardiac arrest leading to coma, successful return of spontaneous circulation, and persistent coma after the return of spontaneous circulation.

排除标准

  • pregnancy, cardiogenic shock (systolic blood pressure less than 90 mm Hg despite epinephrine infusion), possible causes of coma other than cardiac arrest (drug overdose, head trauma, or cerebrovascular accident), an underlying background of known acute or chronic disease including renal failure, liver or pulmonary disorders, previous stroke, dementia, and brain injury.

研究组 & 干预措施

mlc-901 group

Experimental

干预措施: MLC 901 (Drug)

placebo group

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

neurofunctional outcome using Glasgow Outcome Scale (GOS)

时间窗: 6 months

neurofunctional outcome using modified Rankin Scale (mRS)

时间窗: 6 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ali Amini Harandi

associate professor

Shahid Beheshti University of Medical Sciences

研究点 (1)

Loading locations...

相似试验